7[4]Arner P.Free fatty acids-do they play a central role in type 2diabetes.Diabetes,Obesity & Metabolism,2001,3 (Suppl.1):S11-S19
8[5]Banerji M,Lebovitz HE & Dugbartey M.Rosiglitazone selectively increases subcutaneous but not visceral adipose tissue mass in type 2 diabetes mellitus.Diabetes,2001,50 (Suppl 2):A90
9[6]Smith S,Boam DS,Bretherton-Watt D,et al.Rosiglitazone increases pancreatic islet area,density and insulin content,but not insulin gene expression.Diabetes,1998,47 (Suppl.1):A18
10[7]Patel J,Weston WM & Hemyari P.Rosiglitazone (RSG) decreases insulin resistance (IR) and improves beta-cell function (BCF) in patients with type 2 diabetes mellitus.Endocrine Society 81st Annual Meeting:Program and Abstracts,1999,470:Abstract P3-P153
